Drug Profile
Research programme: respiratory disease therapy - Archemix
Alternative Names: Anti-IgE aptamers - ArchemixLatest Information Update: 27 Apr 2007
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Class
- Mechanism of Action Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma; Peanut hypersensitivity
Most Recent Events
- 17 Aug 2005 This programme is still in active development - (BIO-2005)
- 27 Jul 2004 Preclinical trials in Allergic rhinitis in USA (SC)
- 27 Jul 2004 Preclinical trials in Asthma in USA (SC)